Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 458

Sort by

Sort Order Select

Journal Articles

Hemopexin deficiency promotes acute kidney injury in sickle cell disease

Solomon F. Ofori-Acquah, Rimi Hazra, Oluwaseun O. Orikogbo, Danielle Crosby, Bethany Flage, Ezekiel B. Ackah, Diane Lenhart, Roderick J. Tan, Dario A. Vitturi, Vivian Paintsil, Ellis Owusu-Dabo, Samit Ghosh, in collaboration with the SickleGenAfrica Network

Blood (2020) 135 (13): 1044–1048.

https://doi.org/10.1182/blood.2019002653

Published: 2020

Includes: Supplemental data

Journal Articles

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Pallavi Kopparthy, MD, Anita Rajasekhar, MD

Blood (2019) 134 (Supplement_1): 4899.

https://doi.org/10.1182/blood-2019-131846

Published: 2019

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD

Blood (2019) 134 (Supplement_1): 1891.

https://doi.org/10.1182/blood-2019-127076

Published: 2019

Journal Articles

Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate

Jason N Barreto, PharmD, Erin F Barreto, PharmD, Kristen T Peterson, PharmD, Ross Dierkhising, MS, Kristin C. Mara, MS., Nelson Leung, MD, Carrie A. Thompson, MD

Blood (2019) 134 (Supplement_1): 1621.

https://doi.org/10.1182/blood-2019-123281

Published: 2019

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

https://doi.org/10.1182/blood-2019-126385

Published: 2019

Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 1626.

https://doi.org/10.1182/blood-2019-127349

Published: 2019

Journal Articles

Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes

Heather Personett May, PharmD, Erin F Barreto, PharmD, Kristin C. Mara, MS., Kristen McCullough, PharmD, Nelson Leung, MD, Thomas M. Habermann, MD

Blood (2019) 134 (Supplement_1): 1628.

https://doi.org/10.1182/blood-2019-131149

Published: 2019

Journal Articles

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, MD, Maria Roussou, MD, Eftathios Kastritis, Alexandra Margeli, PhD, Evangelos Eleutherakis-Papaiakovou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Gerasimos-Petros Papassotiriou, PhD, Despina Fotiou, MD, Magdalini Migkou, MD, Maria Gavriatopoulou, MD, Erasmia Psimenou, MD, Ioannis Papassotiriou, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 1877.

https://doi.org/10.1182/blood-2019-123912

Published: 2019

Journal Articles

Relationship between Vaso-Occlusive Crises and Important Complications in Sickle Cell Disease Patients

Miranda Bailey, Ajibola Abioye, George Morgan, Tom Burke, MSc, Tim Disher, Stephen Brown, Ashley Bonner, Eleonore Herquelot, Ludovic Lamarsalle, Fanny Raguideau

Blood (2019) 134 (Supplement_1): 2167.

https://doi.org/10.1182/blood-2019-131721

Published: 2019

Journal Articles

Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials

Natalia Scaramellini, MD, Carola Arighi, MD, Alessia Marcon, MD, Dario Consonni, MD, Elena Cassinerio, MD, Giovanna Graziadei, MD, Maria Domenica Cappellini, MD, Irene Motta, MD

Blood (2019) 134 (Supplement_1): 3542.

https://doi.org/10.1182/blood-2019-130237

Published: 2019

Journal Articles

The Role of Monitoring Complement Levels in Catastrophic Antiphospholipid Syndrome: A Case Series of 4 Patients

Lauren M Panebianco, MD, Teresa Gentile, MD PhD

Blood (2019) 134 (Supplement_1): 4872.

https://doi.org/10.1182/blood-2019-128297

Published: 2019

Journal Articles

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Andrea Piolatto, MS, Carmen Gaglioti, MD, Filomena Longo, MD, Silvia De Francia, PhD, Sarah Allegra, PhD, Paola Berchialla, PhD, Antonio Piga

Blood (2019) 134 (Supplement_1): 3547.

https://doi.org/10.1182/blood-2019-122030

Published: 2019

Journal Articles

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors

Ghassan Al-Shbool, MD, Sameer Desale, MS, Judith Veis, MD, Vera Malkovska, MD, Sanjal Desai, MD

Blood (2019) 134 (Supplement_1): 2912.

https://doi.org/10.1182/blood-2019-129558

Published: 2019

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Ka-Won Kang, Hyemi Moon, Byung-Hyun Lee, MD, Min Ji Jeon, Eun Sang Yu, MD, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD PhD, Chul Won Choi, Byung Soo Kim, Juneyoung Lee, Yong Park

Blood (2019) 134 (Supplement_1): 2227.

https://doi.org/10.1182/blood-2019-125269

Published: 2019

Journal Articles

Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

William E Plautz, BS, Mitchell Dyer, MD MSc, Margaret V. Ragni, MD MPH, Shannon Haldeman, Wyeth E Alexander, BS, Jason Sperry, Francis Guyette, Brian Zuckerbraun, Marian A. Rollins-Raval, MD MHP, Jay S Raval, MD, Matthew D Neal, MD

Blood (2019) 134 (Supplement_1): 444.

https://doi.org/10.1182/blood-2019-124531

Published: 2019

Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 237.

https://doi.org/10.1182/blood-2019-124866

Published: 2019

Journal Articles

Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis

Blood (2019) 134 (Supplement_1): 80.

https://doi.org/10.1182/blood-2019-124477

Published: 2019

Journal Articles

Hemopexin Replacement Therapy Protects Sickle Cell Disease Mice from Acute Kidney Injury

Samit Ghosh, Oluwaseun Orikogbo, Rimi Hazra, Bethany Flage, Danielle Crosby, Solomon Fiifi Ofori-Acquah

Blood (2019) 134 (Supplement_1): 78.

https://doi.org/10.1182/blood-2019-127161

Published: 2019

NARROW

Hemopexin deficiency promotes acute kidney injury in sickle cell disease

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Relationship between Vaso-Occlusive Crises and Important Complications in Sickle Cell Disease Patients

Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials

The Role of Monitoring Complement Levels in Catastrophic Antiphospholipid Syndrome: A Case Series of 4 Patients

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis

Hemopexin Replacement Therapy Protects Sickle Cell Disease Mice from Acute Kidney Injury

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only